Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1Burkitt Lymphoma 1

Interventions

Brentuximab Vedotin 7dacetuzumab 4Lenalidomide 3Doxorubicin 3Dexamethasone 3spartalizumab 2lintuzumab 2fludarabine 2Vincristine 2Rituximab 2Rifampin 2Prednisone 2Gemcitabine 2Cyclophosphamide 2tanespimycin 1sabatolimab 1pomalidomide 1pirtobrutinib 1fludarabine phosphate 1ficlatuzumab 1daratumumab 1Vinblastine 1Thiotepa 1TAS4464 1Sertraline 1R-CHOP protocol 1Pam2CSK4 acetate and ODN M362 combination 1Midazolam 1Melphalan 1LCL161 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Diseases × pirtobrutinib × Clear all
NCT05024045 2026-03-03

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Eli Lilly and Company

Phase 1 Active not recruiting
316 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡